Short Interest in enGene Holdings Inc. (NASDAQ:ENGN) Drops By 93.4%

enGene Holdings Inc. (NASDAQ:ENGN) saw a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 50,600 shares, a decrease of 93.4% from the November 30th total of 768,300 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily volume of 207,100 shares, the short-interest ratio is presently 0.2 days.

enGene Trading Up 4.6 %

Shares of ENGN stock traded up $0.28 on Friday, reaching $6.42. 67,687 shares of the stock were exchanged, compared to its average volume of 117,836. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09. The stock has a market cap of $283.87 million, a P/E ratio of -11.07 and a beta of -0.78. The firm has a 50 day moving average of $7.89 and a two-hundred day moving average of $7.73. enGene has a 1-year low of $4.42 and a 1-year high of $18.40.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. On average, research analysts anticipate that enGene will post -1.52 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ENGN shares. Oppenheimer reissued an “outperform” rating and set a $30.00 price target on shares of enGene in a research report on Tuesday, September 24th. Raymond James started coverage on enGene in a research report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price objective for the company. Morgan Stanley restated an “overweight” rating and issued a $40.00 target price on shares of enGene in a report on Wednesday, September 11th. Citizens Jmp upgraded shares of enGene to a “strong-buy” rating in a report on Monday, November 18th. Finally, JMP Securities reissued a “market outperform” rating and set a $18.00 price objective on shares of enGene in a research note on Monday, December 23rd. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $29.78.

Insider Buying and Selling at enGene

In other enGene news, major shareholder Growth Opportunities F. Forbion acquired 11,844 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was acquired at an average cost of $6.55 per share, with a total value of $77,578.20. Following the purchase, the insider now directly owns 2,469,833 shares in the company, valued at approximately $16,177,406.15. This trade represents a 0.48 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Over the last 90 days, insiders have bought 369,326 shares of company stock valued at $2,345,518. Insiders own 13.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ENGN. Wolverine Asset Management LLC purchased a new position in shares of enGene in the 3rd quarter valued at $37,000. Point72 Asset Management L.P. increased its holdings in enGene by 1,410.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after purchasing an additional 619,100 shares in the last quarter. SR One Capital Management LP purchased a new position in enGene in the second quarter valued at about $4,715,000. Franklin Resources Inc. lifted its stake in shares of enGene by 48.7% during the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after purchasing an additional 389,918 shares in the last quarter. Finally, Logos Global Management LP boosted its position in shares of enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after buying an additional 400,000 shares during the period. 64.16% of the stock is owned by institutional investors and hedge funds.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.